Newsroom der German Breast Group
In unserem Newsroom finden Sie Aktuelles rund um die German Breast Group.
09.09.2021 GBG Jahrestreffen 2022 - Save the date
Wir freuen uns Sie beim virtuellen GBG Jahrestreffen 2022 begrüßen zu dürfen, vom 9.-11.März 2022. Bitte reservieren/notieren Sie sich bereits das Datum. Alle weiteren Informationen folgen. Ihr Event-Team
06.09.2021 GBG research at ESMO 2021
We are happy to present our work at ESMO 2021, September 16-21th
30.08.2021 August 2021: Utility of the CPS + EG scoring system in TNBC patients treated with neoadjuvant chemotherapy
We are delighted to inform you that our analysis on the utility of the CPS + EG score in triple-negative breast cancer patients has been published in European Journal of Cancer
19.07.2021 July 2021: Clinical and molecular characteristics of HER2-low-positive breast cancer
We are pleased to inform you that a pooled analysis of patients with HER2-low-positive breast cancer has been published in The Lancet Oncology
30.06.2021 June 2021: Chemotherapy-induced ovarian failure in young women with early breast cancer
A prospective analysis on chemotherapy-induced ovarian failure in young women with early breast cancer has been published in European Journal of Cancer
15.06.2021 Update-Seminar Klinische Pharmazie im September
Veranstaltungsempfehlung: 12. Klinische Pharmazie-Update-Seminar, 10. und 11. September 2021, Wiesbaden
01.06.2021 May 2021: Therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer
A pooled analysis on therapy response and prognosis of patients with low HR-positive, HER2-negative early breast cancer has been published in European Journal of Cancer
21.05.2021 GBG research at ASCO Virtual Meeting
We are happy to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ASCO Annual Meeting 2021, which will take place from 4 to 8 June.
23.04.2021 Please participate in the TILs-Survey
The International Immuno-Oncology Biomarker Working Group has launched a global survey on the potential use of Tumor Infiltrating Lymphocytes (TILs) for future trial designs and use in daily practice.
20.04.2021 GBG Research at ESMO Breast Cancer Virtual Meeting 2021
We are delighted to inform you that results of several research projects from GBG and collaborative groups will be presented at the upcoming ESMO Breast Cancer Virtual Meeting 2021, which will take place from 5 to 8 May 2021.
13.04.2021 April 2021: First results of the randomized phase III PenelopeB trial
We are delighted to inform you that the first results of the randomized phase III PenelopeB trial have been published on a Rapid Communications basis in Journal of Clinical Oncology.
13.04.2021 March 2021: Predicting prognosis of breast cancer patients with brain metastases
An analysis including breast cancer patients with brain metastases from the BMBC registry has been published in Cancers
29.03.2021 ESMO BREAST CANCER 2021 - Virtual Meeting
Registration for the ESMO Breast Cancer Virtual Meeting, taking place 5-8 May 2021 is now open.
01.03.2021 Vorträge des Jahrestreffens verfügbar
Wir danken den Referenten, Teilnehmern und Organisatoren für das tolle virtuelle Jahrestreffen. Die Präsentationen finden Sie auf unserer Website zum Download und als Video zum Nachhören.
01.03.2021 17th St.Gallen International Breast Cancer Conference 2021
The 17th St.Gallen International Breast Cancer Conference is going fully virtual!
28.02.2021 February 2021: Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer
A translational research project investigating genomic patterns of mutational signatures in breast cancer patients from GeparSepto trial has been published in Annals of Oncology.
26.02.2021 January 2021: Final results of the MALE study
We are delighted to inform you that final results of the first randomized phase II MALE trial have been published in JAMA Oncology.
17.02.2021 OlympiA trial crossed superiority boundary for invasive disease-free survival
IDMC has concluded that OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis. OlympiA Phase III trial of Lynparza in the adjuvant treatment of BRCA-mutated HER2-negative high-risk early breast cancer will be analysed and reported early.
